As filed with the Securities and Exchange Commission on April 26, 2022
Registration
No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Ambrx Biopharma Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Cayman Islands |
|
Not applicable |
(State or other jurisdiction of
Incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
10975 North Torrey Pines Road
La Jolla, California 92037, United States
(Address of principal executive offices) (Zip code)
2021 Equity
Incentive Plan
2021 Employee Share Purchase Program
(Full title of the plan)
Feng Tian,
Ph.D.
President, Chief Executive Officer and Chairman of the Board of Directors
Ambrx Biopharma Inc.
10975 North Torrey Pines Road
La Jolla, California 92037, United States
(858) 875-2400
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Patrick Loofbourrow
Carlos Ramirez
Cooley
LLP
4401 Eastgate Mall
San Diego, California 92121
+1 858 550 6000
Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large
accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☐ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒